Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 6/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PHGDH | O43175 | 1/20 | 0.41 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2190889 | 0.89 | CRHR1 (0.54) | CRHR1CYP1A2CYP2C19PHGDHTRAP1 | |
| SCHEMBL2193222 | 0.83 | CRHR1 (0.49) | CRHR1PHGDHMAPTSMN1; SMN2 | |
| SCHEMBL5489896 | 0.80 | CRHR1 (0.40) | CRHR1CYP1A2CYP2C19PHGDHSCN9A | |
| SCHEMBL5489892 | 0.80 | CRHR1 (0.42) | CRHR1 | |
| SCHEMBL5497563 | 0.78 | CRHR1 (0.46) | CRHR1CYP2C19 | |
| SCHEMBL5489898 | 0.78 | CRHR1 (0.42) | CRHR1CYP1A2CYP2C19PHGDHTRAP1 | |
| SCHEMBL5489901 | 0.78 | CRHR1 (0.41) | CRHR1CYP1A2CYP2C19PHGDHSCN9A | |
| SCHEMBL5497573 | 0.78 | CRHR1 (0.41) | CRHR1CYP1A2CYP2C19PHGDHSCN9A | |
| SCHEMBL6746260 | 0.78 | CRHR1 (0.41) | CRHR1CYP1A2CYP2C19PHGDHTRAP1 | |
| SCHEMBL3282113 | 0.77 | CRHR1 (0.45) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279474-B2 | Substituted pyrrolo[2,3-d]pyrimidines as antagonists of the corticotropin releasing factor (CRF) | GLAXO GROUP LIMITED (GB) | 2007-10-09 | — | — | US | disclosed |
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | GLAXO GROUP LIMITED (GB) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | CRH, CRHR1, CRHR2 | CRHR1 2/4885CYP1A2 1826/4885CYP2C19 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.